Key Drivers
- Strong Profitability
- Rising Liquidity
- High Leverage
AIAI Summary
Amgen's investment case is shifting from a defensive dividend play to a leveraged pipeline-execution story: strong cash flow and diversified growth can offset patent losses, but at ~25x earnings investors should await tangible IMDELLTRA/Repatha traction and debt reduction before underwriting a sustained re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Profitability
- •Rising Liquidity
- •High Leverage
Amgen's strong margins, cash flow, and liquidity are offset by elevated debt and a premium valuation, warranting caution on leverage.
Price Behavior
Key Price Behavior Insights:
- •Bearish trend
- •Oversold rebound
- •Key resistance
AMGN remains bearish over the last month, though an oversold rebound from $375–$377 support warrants caution until it reclaims $391–$393 resistance.
Sharp drop from $444.12 on 2026-09-03 to $393.17 on 2026-09-08
Sentiment & News
Key News Insights:
- •Raised guidance
- •Pipeline momentum
- •Pricing risks
Amgen's raised guidance, broad product growth and pipeline momentum support a positive outlook, though patent, pricing and valuation risks warrant caution.
The news is moderately positive for Amgen shares, with growth catalysts offset by ongoing competitive and valuation pressures
Similar Companies in Healthcare
Other companies in the same sector with AI ratings